Catriona Yale
CIK 1779308 · Chief Development Officer · last filed 2025-12-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
63
Lifetime Open-Market Net
-$17.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) Delisted | Chief Development Officer | 0 | $54.65 | $0 | -$17.93M | 52 | 2025-12-09 |
Recent Filings · Page 2 of 7
63 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-16 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$152.5K | EDGAR |
| 2025-03-18 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$236.6K | EDGAR |
| 2025-03-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −614 | -$27.6K | EDGAR |
| 2025-02-21 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$287.7K | EDGAR |
| 2025-01-31 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$2.45M | EDGAR |
| 2025-01-31 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.70M | EDGAR |
| 2025-01-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Notice (144) | −53,591 | -$1.40M | EDGAR |
| 2025-01-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Notice (144) | −69,073 | -$1.81M | EDGAR |
| 2024-12-18 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | +24,300 | -$72.7K | EDGAR |
| 2024-12-12 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −2,810 | -$86.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.